CopySight AI has raised $3.0M in a seed round, a bet that the biggest bottleneck for AI-generated content isn’t technical-it’s legal. The startup’s platform is built for enterprise and entertainment studios that want to use AI without tripping over copyright claims or IP infringement risks, offering tools to verify copyrightability and flag potential legal landmines before content ships. The funding arrives as studios and corporations increasingly demand guardrails around generative tools, though the company hasn’t disclosed who’s backing the round. For now, the capital gives CopySight room to push its compliance layer deeper into production workflows, where the stakes-and the potential payoffs-are highest.
CopySight AI Raises $3.0M Seed Round
Get the full CopySight AI company profile
Access contacts, investors, buying signals & more
Other United States companies recently funded
View all
Cirrus Therapeutics
Cirrus Therapeutics is an ocular immunology-focused company co-founded by Dr. Kai Chan, former Chief Scientific Officer of Ally Therapeutics and Blavatnik Fellow at Harvard Business School, and Dr. Andrew Dick, Professor and Head of the Academic Unit of Ophthalmology at the University of Bristol and Director of UCL Institute of Ophthalmology. Cirrus, a spin-out from the University of Bristol, is developing treatments for long-term eye diseases that can cause blindness, focusing on conditions that affect the ocular immune system. Cirrus’ lead program is a differentiated and first-in-class approach to treating dry age-related macular degeneration (AMD), the leading cause of vision loss among older adults. Dr. Dick, Dr. Chan, and colleagues found that increasing the protein IRAK-M in retinal cells can significantly protect against retinal degeneration. This discovery will build and improve upon current treatments for AMD, which only have the capacity to address single pathophysiology pathways. Cirrus’ novel approach not only addresses the multiple pathways involved in treating AMD but also offers the most compelling and evidence-based strategy available today. MARKET POTENTIAL The AMD market is rapidly growing—especially as global populations age—and is expected to reach $27.5 billion by 2031.
$14.7M Seed
today
Biggest recent Legal rounds
Largest funding rounds in Legal on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Legal Tech Germany | Grant | $6.0B | 6mo ago |
| 2 |  Legalcomplex | Seed | $6.0B | 7mo ago |
| 3 |
Other recent Seed rounds
Companies that recently closed a Seed round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 | Cirrus Therapeutics United States | Seed | $14.7M | today |
| 2 |  Noscen United States | Seed | $5.5M | today |
